About me
Paulette Robinson, PhD, RAC is the Senior Director, Regulatory Affairs at Neurogene Inc. Her regulatory affairs experience has focused on gene therapies in rare central nervous system and ophthalmic indications. She continues to lead the global regulatory strategy for the NGN-401 program through successful interactions and negotiations with health authorities including the FDA, MHRA and TGA on complex topics leading to initiation of rare disease clinical trials. The NGN-401 program has received multiple designations (Orphan Drug Designations globally, Rare Pediatric Disease Designation, Fast-track, RMAT and PRIME) and pilot programs (ILAP 1.0 and START). She has obtained her Ph.D from the University of Florida in genetics.
